unknown
Stage
1
Investors
About
GlycoMimetics is a biotechnology company developing glycomimetic therapeutics that target selectin-mediated cell adhesion to treat hematologic disorders and cancer; clinical-stage candidates have included uproleselan (GMI-1271) for acute myeloid leukemia and rivipansel (GMI-1070) for vaso-occlusive crises in sickle cell disease.
Explore GlycoMimetics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.